HDAC9 and cancer: Several early findings led to increasing interest in HDAC inhibitors (HDACis) as potent anticancer therapeutics—e.g., histone H4 is commonly deacetylated in human primary malignancies [12] and HDAC family members are frequently overexpressed in a variety of human cancers [13,14,15,16,17].